NEWS & EVENTS
List
Icon
-
GBC Signed a MOU with Sinphar Group to Strengthen the Development of Oncology (Cytotoxic) DrugsMORE > -
GBC Strengthened Strategic Cooperation with Alar Pharm, New Drug (Prolonged-release, P.R.) DeveloperMORE > -
Taiwan FDA granted Market License of Fulvestrant Lyophilized Injection 250mg "GBC"MORE > -
Taiwan FDA granted the API Market License of Fulvestrant "GBC"MORE > -
GBC obtained the qualification approval letter from the Bureau of Industry of the Ministry of Economic Affairs for "Entrusting Domestic Pharmaceutical R&D Service Companies for the Biotechnology and Pharmaceutical Industry" and was included in the referenMORE > -
Zhunan Site Dedicated Peptide Synthesis Teriparatide API Plant obtained Taiwan FDA PIC/S GMP Certification.MORE >